Related Experiment Video

Updated: Jun 10, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Computational analysis of mTOR signaling pathway: bifurcation, carcinogenesis, and drug discovery

Guanyu Wang1, Gerhard R F Krueger

  • 1Department of Physics, The George Washington University, 725 21st Street, N.W., Washington, DC 20052, USA. gwang@gwu.edu

Anticancer Research
|August 5, 2010
PubMed

Insights

Molecularly targeted cancer therapy shows promise for reduced toxicity. Computational analysis of signaling pathways, like mTOR, can reveal synergistic drug targets for improved cancer treatment.

Area of Science:

  • Oncology
  • Computational Biology
  • Pharmacology

Background:

  • Molecularly targeted therapeutics offer improved efficacy and reduced toxicity compared to traditional chemotherapy.
  • Cancer signaling networks are complex, necessitating simultaneous targeting of multiple molecules for synergistic effects.
  • Mathematical modeling and computer simulations are crucial for understanding network dynamics and simulating therapeutic interventions.

Purpose of the Study:

  • To demonstrate the utility of computational analysis in understanding cancer pathogenesis.
  • To identify potential therapeutic interventions by simulating the effects of targeting multiple molecules.
  • To explore the mTOR signaling pathway as a model system for computational drug discovery.

Main Methods:

  • Utilizing mathematical modeling and computer simulations to represent the mTOR signaling pathway.
  • Perturbing multiple parameters within the model to simulate the effects of simultaneous molecular targeting.
  • Analyzing the parameter space to identify key relationships and synergistic effects.

Main Results:

  • Identified a composite parameter that effectively summarizes the synergistic effects of four distinct parameters.
  • Demonstrated that computational analysis provides significant insights into cancer pathogenesis.
  • Revealed the potential for developing novel therapeutic strategies through in silico simulations.

Conclusions:

  • Computational analysis of signaling pathways, exemplified by mTOR, offers valuable insights into cancer development.
  • The identified composite parameter and parameter space geometry can guide the development of low-dosage, minimal-toxicity cancer drugs.
  • This approach holds promise for advancing precision medicine in oncology.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...